On 17 July 2012, orphan designation (EU/3/12/1020) was granted by the European Commission to Appletree Europe S.a.r.l., Luxemburg, for recombinant human pentraxin-2 for the treatment of idiopathic pulmonary fibrosis.
The sponsorship was transferred to FGK Representative Service GmbH, Germany, in April 2014.
The sponsorship was transferred to Roche Registration GmbH, Germany, in April 2020.
Recombinant human pentraxin-2
|Disease / condition||
Treatment of idiopathic pulmonary fibrosis
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.